Cuban scientists are optimistic about the results of the vaccine trial to treat lung cancer

During a meeting on the same day with Cuban President Miguel Díaz-Canel, researcher Tania Crombet of Cuba’s Center for Molecular Immunology provided detailed information on the research stages of this vaccine – The only pharmaceutical in the world to use immunotherapy to treat certain forms of lung cancer.

According to Ms. Crombet, CIMAvax-EGF is one of the leading drugs being tested in the US in the cooperation program of Roswell Park Institute. The US regulatory agency has recommended using this vaccine for the most severe group of patients.

Meanwhile, experts from the Hermanos Ameijeiras Hospital in Havana confirmed that the CIMAvax-EGF vaccine helps prolong the life of patients treated at this hospital.

CIMAvax-EGF, developed by the Cuban Center for Molecular Immunology, is the world’s first immunotherapy vaccine specifically for lung cancer patients to prevent disease recurrence. To get this vaccine, patients must first complete chemotherapy and radiation therapy.

According to the researchers, unlike the mechanism of action of other lung cancer drugs that directly attack cancer cells, CIMAvax-EGF helps the body produce antibodies to prevent cancer and slow down the process of cancer. growth of cancer cells, helping to prolong the patient’s life.